Open AccessSomatostatin Receptor Ligand Therapy—A Potential Therapy for Neurocytoma
Author(s) -
Dongyun Zhang,
Sarah S R Kim,
Daniel F. Kelly,
L. Sylvia,
Masoud Movassaghi,
Sergey Mareninov,
William H. Yong,
Timothy F. Cloughesy,
Fausto J. Rodríguez,
Paul E. McKeever,
Qian Jiang,
Jian Yi Li,
Qinwen Mao,
Kathy L. Newell,
Richard M. Green,
Cynthia T. Welsh,
Zhenggang Xiong,
Anthony P. Heaney
Publication year - 2019
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2018-02419
Subject(s) - radionuclide therapy , medicine , lanreotide , somatostatin , somatostatin receptor , central neurocytoma , somatostatin receptor 2 , adjuvant therapy , fluorodeoxyglucose , radiation therapy , regimen , nuclear medicine , positron emission tomography , chemotherapy , radiology , magnetic resonance imaging , growth hormone , hormone , acromegaly
Neurocytoma (NC) is a rare, low-grade tumor of the central nervous system, with a 10-year survival rate of 90% and local control rate of 74%. However, 25% of NCs will be atypical, with an elevated Ki-67 labeling index >2%, and will exhibit a more aggressive course, with a high propensity for local recurrence and/or craniospinal dissemination. Although no standard treatment regimen exists for these atypical cases, adjuvant stereotactic or conventional radiotherapy and/or chemotherapy have been typically offered but have yielded inconsistent results.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom